Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Chronically infected with Hepatitis C Virus (HCV) genotype 1~* Treatment naive or treatment non-responders or treatment intolerant; and not co-infected with HIV or Hepatitis B Virus~* HCV RNA viral load of ≥10\*5 IU/mL~* BMI 18 to 35kg/m²~Exclusion Criteria:~* Any significant acute or chronic medical illness which is not stable or is not controlled with medication and not consistent with Hepatitis C Virus infection~* HIV and/or HBV positive~* Major surgery within 4 weeks of study drug administration and any gastrointestinal surgery that could impact the absorption of study drug~WOCBP will be enrolled as in-patient for 16 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Daclatasvir (1 mg), once daily~or~Matching Placebo, once daily
- Group 2 (Type: ACTIVE_COMPARATOR): Daclatasvir (10 mg), once daily~or~Matching Placebo, once daily
- Group 3 (Type: ACTIVE_COMPARATOR): Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily
- Group 4 (Type: ACTIVE_COMPARATOR): Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily
- Group 5 (Type: ACTIVE_COMPARATOR): Group 5: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily
- Group 6 (Type: ACTIVE_COMPARATOR): Group 6: Active Comparator~Daclatasvir (1-100 mg), once or twice daily~or~Matching Placebo, once or twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).